(FLSW) FTSE Switzerland - Overview
Etf: Stocks, Swiss, Large-Cap, Mid-Cap, ETF
Dividends
| Dividend Yield | 2.39% |
| Yield on Cost 5y | 3.21% |
| Yield CAGR 5y | 6.79% |
| Payout Consistency | 89.3% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 13.7% |
| Relative Tail Risk | 0.09% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.44 |
| Alpha | 19.30 |
| Character TTM | |
|---|---|
| Beta | 0.431 |
| Beta Downside | 0.293 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.03% |
| CAGR/Max DD | 1.18 |
Description: FLSW FTSE Switzerland January 08, 2026
Franklin FTSE Switzerland ETF (NYSE ARCA: FLSW) seeks to track the FTSE Switzerland Capped Index by allocating at least 80 % of its net assets to the index’s constituent equities and related depository receipts. The underlying index represents large- and mid-cap Swiss companies, and the fund’s non-diversified structure means concentration risk is higher than in broadly diversified ETFs.
Key metrics (as of the most recent filing) include an expense ratio of 0.20 % and a weighted average market-cap of roughly CHF 45 billion, indicating a tilt toward the country’s dominant sectors such as financial services, pharmaceuticals, and consumer staples. The top five holdings typically comprise UBS Group AG, Novartis AG, Roche Holding AG, Credit Suisse Group AG (subject to recent restructuring), and Nestlé SA, together accounting for about 30 % of assets.
Switzerland’s economic backdrop-characterized by a strong Swiss franc, low inflation, and a robust export-driven manufacturing base-directly influences the ETF’s performance. In particular, the banking sector’s exposure to global interest-rate cycles and the pharmaceutical industry’s pipeline developments are primary drivers of returns.
For a deeper, data-rich analysis of FLSW’s risk-adjusted performance and sector sensitivities, you may find the ValueRay platform useful.
What is the price of FLSW shares?
Over the past week, the price has changed by +2.33%, over one month by +3.99%, over three months by +14.31% and over the past year by +29.02%.
Is FLSW a buy, sell or hold?
What are the forecasts/targets for the FLSW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 50.8 | 16.5% |
FLSW Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 66.7m USD (66.7m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 66.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 66.7m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.50% (E(66.7m)/V(66.7m) * Re(7.50%) + (debt-free company))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)